Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17606455rdf:typepubmed:Citationlld:pubmed
pubmed-article:17606455lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C1333568lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0023487lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0010802lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0052416lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0175668lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:17606455lifeskim:mentionsumls-concept:C1518321lld:lifeskim
pubmed-article:17606455pubmed:issue7lld:pubmed
pubmed-article:17606455pubmed:dateCreated2007-7-3lld:pubmed
pubmed-article:17606455pubmed:abstractTextNinety-eight newly diagnosed cases of PML-RARalpha positive APL were treated with a regimen of single agent ATO. FLT3 activating mutations were seen in 33% and an additional cytogenetic finding was noted in 23.2%. FLT3 activating mutations were significantly associated with a bcr3 PML-RARalpha isoform (p=0.012) and a delay in achieving a molecular remission (p=0.022). Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clinical outcome.lld:pubmed
pubmed-article:17606455pubmed:languageenglld:pubmed
pubmed-article:17606455pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17606455pubmed:citationSubsetIMlld:pubmed
pubmed-article:17606455pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17606455pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17606455pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17606455pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17606455pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17606455pubmed:statusMEDLINElld:pubmed
pubmed-article:17606455pubmed:monthJullld:pubmed
pubmed-article:17606455pubmed:issn1592-8721lld:pubmed
pubmed-article:17606455pubmed:authorpubmed-author:GeorgeBijuBlld:pubmed
pubmed-article:17606455pubmed:authorpubmed-author:SrivastavaAlo...lld:pubmed
pubmed-article:17606455pubmed:authorpubmed-author:MathewsVikram...lld:pubmed
pubmed-article:17606455pubmed:authorpubmed-author:ChandyMammenMlld:pubmed
pubmed-article:17606455pubmed:authorpubmed-author:ThomasMariaMlld:pubmed
pubmed-article:17606455pubmed:authorpubmed-author:SrivastavaViv...lld:pubmed
pubmed-article:17606455pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17606455pubmed:volume92lld:pubmed
pubmed-article:17606455pubmed:ownerNLMlld:pubmed
pubmed-article:17606455pubmed:authorsCompleteYlld:pubmed
pubmed-article:17606455pubmed:pagination994-5lld:pubmed
pubmed-article:17606455pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:meshHeadingpubmed-meshheading:17606455...lld:pubmed
pubmed-article:17606455pubmed:year2007lld:pubmed
pubmed-article:17606455pubmed:articleTitleImpact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.lld:pubmed
pubmed-article:17606455pubmed:affiliationDepartment of Haematology, Christian Medical College, Vellore, 632004 India. vikram@cmcvellore.ac.inlld:pubmed
pubmed-article:17606455pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:2322entrezgene:pubmedpubmed-article:17606455lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17606455lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17606455lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17606455lld:pubmed